Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MindMed

Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026

As mental health treatment evolves, MindMed’s advancing psychedelic pipeline and strong 2025 rally have Jones Trading penciling in gains that could more than quadruple the stock from here.

Barchart

MarketBeat’s Top 5 Rated Small-Cap Stocks

Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment.

MarketBeat

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health disorders.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The Insider Report: Panic Never Pays

It was a pretty quiet week until Friday. Trade tensions with China are soaring again, and it sent stocks tumbling into the close. Could we really see 100% tariffs on China? I think it's an exaggeration, and the best dip buying opportunity in months. Be ready. The Dow Jones Industrial…

Benzinga

LSD shows promise for reducing anxiety, shows drugmaker's study

The psychedelic drug LSD showed positive results for easing symptoms in people with generalised anxiety disorder, a recent study has shown.

Euronews

LSD shows promise for reducing anxiety in drugmaker's midstage study

A midstage study of the psychedelic drug LSD showed positive results for easing symptoms in people with generalized anxiety disorder

The Independent UK

Researchers pinpoint LSD dose that could keep anxiety at bay for weeks

A trial explored the effect of MM120, a new pharmaceutically optimised dissolvable LSD tablet, on patients with generalised anxiety disorder.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Experts reveal the exact LSD dose that can ease anxiety for weeks

A new trial examined the effect of a new dissolvable LSD tablet on patients with generalised anxiety disorder

The Independent UK

Could This Psychedelic Drug Stock Be a Top Buy for 2026?

With Phase 3 results for its lead psychedelic therapy expected next year, is now the right time to take a bold bet on MNMD stock?

Barchart

1 Small-Cap Biotech That Analysts Expect to Triple

As psychedelic treatments gain traction, analysts predict triple-digit upside for this small-cap biotech stock.

Barchart

Buy the Dip in This Biotech After Negative FDA News, Says Analyst

MindMed is a high-flying pre-revenue company that has more than doubled investor returns in the last 12 months.

Barchart

Do psychedelics require a therapist?

Are drugs like psilocybin and MDMA still safe and effective in the absence of psychotherapy?

Salon

3 Growth Stocks Under $10 With Breakout Potential

Discover three under-the-radar biotech and medtech stocks that analysts believe could soar in 2024, each with unique growth drivers and significant upside potential.

Barchart

Up 163% YTD, Is It Too Late to Buy MindMed Stock?

Mind Medicine is a pre-revenue biopharma company that has more than doubled investor returns in 2024. Is MNMD stock a good buy today?

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials

Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.

Benzinga

Breaking Down Molly: Swiss University Studies How MDMA's Components Might Affect Humans

MindMed’s (NASDAQ: MNMD) recurring collaborator, Prof. Dr.

Miami Herald

Miami clinic kicks off first national study of LSD, once a ‘public enemy,’ to treat anxiety

MIAMI — The gurus of the psychedelic era of American pop culture extolled the experience of the “acid trip.” But the U.S. government and much of the public remained leery of LSD, with President Richard Nixon declaring it and assorted other drugs “public enemy No. 1.”

Benzinga

What's Next For The 20-Year Old Behind $100M Bed Bath & Beyond Trade? Why Jake Freeman Is Focused On This Psychedelics Stock

Bed Bath & Beyond (NASDAQ: BBBY) traders learned last week about Jake Freeman, the 20-year University of Southern California student investor who outsmarted the entire class of "Ape" investors, including GameStop Corp. (NYSE:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

MindMed: Financial And Business Results For Q2 2022, Management And Pipeline Changes

MindMed (NASDAQ: MNMD), which recently received a letter on behalf of one of its shareholders calling for a new business strategy and offer

Benzinga

Does MDMA Reduce Fear? New Study Has Implications For PTSD Treatment

This article was originally published on Psychedelic Spotlight and appears here with permission.

Benzinga

Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company

Medical Psychedelics have made it into Davos, just in time for the World Economic Forum.

Benzinga

Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International

Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department.

Benzinga

MindMed Appoints Schond L. Greenway As CFO

Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.

Benzinga

MindMed Reports Promising Results For Non-Hallucinogenic Ibogaine Congener Substance

MindMed Inc. (NASDAQ: MNMD) reported favorable results for one of its proprietary compounds.

Benzinga

MindMed Reports Financial Results For Q1, With Lower Cash Balance Compared To December Last Year

MindMed (NASDAQ: MNMD) announced its financial results for the first quarter of 2022, which ended March 31.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Psychedelic Spotlight

29 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.